The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
Abstract
PURPOSE: To confirm the promising phase II results of docetaxel monotherapy, this phase III trial was conducted of chemotherapy for patients with advanced non–small-cell lung cancer (NSCLC) who had previously failed platinum-containing chemotherapy. PATIENTS AND METHODS: A total of 373 patients were randomized to receive either docetaxel 100 mg/m 2 (D100) or 75 mg/m 2 (D75) versus a control regimen of vinorelbine or ifosfamide (V/I). The three treatment groups were well-balanced for key patient characteristics. RESULTS: Overall response rates were 10.8% with D100 and 6.7% with D75, each significantly higher than the 0.8% response with V/I (P = .001 and P = .036, respectively). Patients who received docetaxel had a longer time to progression (P = .046, by log-rank test) and a greater progression-free survival at 26 weeks (P = .005, by χ 2 test). Although overall survival was not significantly different between the three groups, the 1-year survival was significantly greater with D75 than with the control treatment (32% v 19%; P = .025, by χ 2 test). Prior exposure to paclitaxel did not decrease the likelihood of response to docetaxel, nor did it impact survival. There was a trend toward greater efficacy in patients whose disease was platinum-resistant rather than platinum-refractory and in patients with performance status of 0 or 1 versus 2. Toxicity was greatest with D100, but the D75 arm was well-tolerated. CONCLUSION: This first randomized trial in this setting demonstrates that D75 every 3 weeks can offer clinically meaningful benefit to patients with advanced NSCLC whose disease has relapsed or progressed after platinum-based chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Non-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 2,850
Landis, S. H., Murray, T., Bolden, S., & Wingo, P. A. (1998) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.48.1.6 · Cited by 2,341
Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?
Grilli, R., Oxman, A. D., & Julian, J. A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1866 · Cited by 382
Quality of Life End Points in Cancer Clinical Trials: Review and Recommendations
Moinpour, C. M., Feigl, P., Metch, B., Hayden, K. A., Meyskens, F. L., & Crowley, J. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.7.485 · Cited by 379
Hollen, P. J., Gralla, R. J., Kris, M. G., & Potanovich, L. M. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80262-x · Cited by 303
Self-citationFossella, F. V., Lee, J. S., Shin, D., Calayag, M. D., Huber, M., Perez-Soler, R., Murphy, W. K., Lippman, S. M., Benner, S. E., & Glisson, B. S. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.645 · Cited by 254
Self-citationGemcitabine as Second-Line Treatment for Advanced Non–Small-Cell Lung Cancer: A Phase II Trial
Crinò, L., Mosconi, A. M., Scagliotti, G., Selvaggi, G., Novello, S., Rinaldi, M., Della Giulia, M., Gridelli, C., Rossi, A., Calandri, C., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2081 · Cited by 162
Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer.
Hainsworth, J. D., Thompson, D. S., & Greco, F. A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1609 · Cited by 160
Cited by
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
“Decreased appetite 30 (10) 0 42 (16) 3 (1)”
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationErlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,874
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Self-citationHanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Self-citationPlanchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
“Docetaxel has shown improved efficacy compared with BSC in randomised trials with a significant improvement in OS in the TAX 320 trial for those patients who received docetaxel at a dose of 75 mg/m(2) every 3 weeks [152, 153].”
MethodShepherd, F. A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O’Rourke, M., Levitan, N., Gressot, L., Vincent, M., Burkes, R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,181
Self-citationJohnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937
Self-citationVemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W., Smith, T. J., Baker Jr, S., Olak, J., Stover, D., Strawn, J. R., Turrisi, A. T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,413
Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Kim, E. S., Hirsh, V., Mok, T., Socinski, M. A., Gervais, R., Wu, Y.-L., Li, L.-Y., Watkins, C. L., Sellers, M. V., Lowe, E. S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61758-4 · Cited by 1,242
A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer
Morse, M. A., Garst, J., Osada, T., Khan, S., Hobeika, A., Clay, T. M., Valente, N., Shreeniwas, R., Sutton, M. A., Delcayre, A., et al. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-9 · Cited by 1,120
Pérez-Soler, R., Chachoua, A., Hammond, L. A., Rowinsky, E. K., Huberman, M., Karp, D., Rigas, J., Clark, G. M., Santabárbara, P., & Bonomi, P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.057 · Cited by 1,070
Self-citationLung cancer: Biology and treatment options
Lemjabbar-Alaoui, H., Hassan, O. U., Yang, Y.-W., & Buchanan, P. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.002 · Cited by 1,014
Fossella, F., Pereira, J. R., von Pawel, J., Pluzanska, A., Gorbounova, V., Kaukel, E., Mattson, K. V., Ramlau, R., Szczęsna, A., Fidias, P., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.046 · Cited by 939
Self-citationMultidisciplinary Management of Lung Cancer
Spira, A., & Ettinger, D. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035536 · Cited by 922
Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Kim, E. S., Herbst, R. S., Wistuba, I. I., Lee, J. J., Blumenschein, G. R., Tsao, A., Stewart, D. J., Hicks, M. E., Erasmus, J., Gupta, S., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0010 · Cited by 889
Self-citation_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 735
Miller, V. A., Kris, M. G., Shah, N., Patel, J., Azzoli, C., Gomez, J., Krug, L. M., Pao, W., Rizvi, N., Pizzo, B., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.158 · Cited by 730
Self-citationEttinger, D. S., Akerley, W., Bepler, G., Blum, M. G., Chang, A., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Demmy, T. L., Ganti, A. K. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0056 · Cited by 730
Self-citationOhe, Y., Ohashi, Y., Kubota, K., Tamura, T., Nakagawa, K., Negoro, S., Nishiwaki, Y., Saijo, N., Ariyoshi, Y., & Fukuoka, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl377 · Cited by 633
Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.013 · Cited by 620
de Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00221-0 · Cited by 619
Carvacrol and human health: A comprehensive review
Sharifi‐Rad, M., Varoni, E. M., Iriti, M., Martorell, M., Setzer, W. N., del Mar Contreras, M., Salehi, B., Soltani‐Nejad, A., Rajabi, S., Tajbakhsh, M., et al. (2018) · Phytotherapy Research · doi:10.1002/ptr.6103 · Cited by 588
Weber, W. A., Petersen, V., Schmidt, B., Tyndale-Hines, L., Link, T., Peschel, C., & Schwaiger, M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.004 · Cited by 493
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
Shaw, A. T., Friboulet, L., Leshchiner, I., Gainor, J. F., Bergqvist, S., Brooun, A., Burke, B. J., Deng, Y.-L., Liu, W., Dardaei, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1508887 · Cited by 484
Garassino, M. C., Martelli, O., Broggini, M., Farina, G., Veronese, S., Rulli, E., Bianchi, F., Bettini, A., Longo, F., Moscetti, L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70310-3 · Cited by 475
Lilenbaum, R. C., Herndon, J. E., List, M. A., Desch, C., Watson, D. M., Miller, A. A., Graziano, S. L., Perry, M. C., Saville, W., Chahinian, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.172 · Cited by 444
Cobo, M., Isla, D., Massuti, B., Montes, A., Sanchez, J. M., Provencio, M., Viñolas, N., Paz-Ares, L., Lopez-Vivanco, G., Muñoz, M. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7915 · Cited by 443
Self-citationFidias, P. M., Dakhil, S. R., Lyss, A. P., Loesch, D. M., Waterhouse, D. M., Bromund, J. L., Chen, R., Hristova-Kazmierski, M., Treat, J., Obasaju, C. K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.1405 · Cited by 418
Herbst, R. S., Sun, Y., Eberhardt, W. E., Germonpré, P., Saijo, N., Zhou, C., Wang, J., Li, L., Kabbinavar, F., Ichinose, Y., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70132-7 · Cited by 415
Peters, S., Gettinger, S., Johnson, M. L., Jänne, P. A., Garassino, M. C., Christoph, D., Toh, C. K., Rizvi, N. A., Chaft, J. E., Carcereny Costa, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9476 · Cited by 400
Cohen, M. H., Gootenberg, J., Keegan, P., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-713 · Cited by 396
Socinski, M. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1335 · Cited by 379
Ciuleanu, T., Stelmakh, L., Cicenas, S., Miliauskas, S., Grigorescu, A. C., Hillenbach, C., Johannsdottir, H. K., Klughammer, B., & Gonzalez, E. E. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70385-0 · Cited by 374
Maruyama, R., Nishiwaki, Y., Tamura, T., Yamamoto, N., Tsuboi, M., Nakagawa, K., Shinkai, T., Negoro, S., Imamura, F., Eguchi, K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0185 · Cited by 367
Nemunaitis, J., Dillman, R. O., Schwarzenberger, P. O., Senzer, N., Cunningham, C., Cutler, J., Tong, A., Kumar, P., Pappen, B., Hamilton, C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.5335 · Cited by 367
Gandara, D. R., Chansky, K., Albain, K. S., Leigh, B. R., Gaspar, L. E., Lara, P. N., Burris, H., Gumerlock, P., Kuebler, J. P., Bearden, J. D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.197 · Cited by 366
Self-citationEttinger, D. S., Akerley, W., Borghaei, H., Chang, A. C., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., Ganti, A. K. P., Govindan, R., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0130 · Cited by 349
Self-citationBepler, G., Kusmartseva, I., Sharma, S., Gautam, A., Cantor, A., Sharma, A., & Simon, G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1101 · Cited by 333
Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer
Socinski, M. A., Novello, S., Brahmer, J. R., Rosell, R., Sanchez, J. M., Belani, C. P., Govindan, R., Atkins, J. N., Gillenwater, H. H., Pallares, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9303 · Cited by 323
Docetaxel for treatment of solid tumours: a systematic review of clinical data
Montero, A., Fossella, F., Hortobagyi, G., & Valero, V. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70094-2 · Cited by 311
Self-citationBezjak, A., Tu, D., Seymour, L., Clark, G., Trajkovic, A., Zukin, M., Ayoub, J., Lago, S., de Albuquerque Ribeiro, R., Gerogianni, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.8073 · Cited by 296
Heymach, J. V., Johnson, B. E., Prager, D., Csada, E., Roubec, J., Pešek, M., Špásová, I., Belani, C. P., Bodrogi, I., Gadgeel, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5122 · Cited by 293
Wu, Y.-L., Planchard, D., Lu, S., Sun, H., Yamamoto, N., Kim, D.-W., Tan, D. S. W., Yang, J. C.-H., Azrif, M., Mitsudomi, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 291
Natale, R. B., Thongprasert, S., Greco, F. A., Thomas, M., Tsai, C.-M., Sunpaweravong, P., Ferry, D., Mulatero, C., Whorf, R., Thompson, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.5981 · Cited by 290
Self-citationChemotherapy and Survival Benefit in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
Davidoff, A. J., Tang, M., Seal, B., & Edelman, M. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4052 · Cited by 290
de Boer, R. H., Arrieta, Ó., Yang, C.-H., Gottfried, M., Chan, V., Raats, J., de Marinis, F., Abratt, R. P., Wolf, J., Blackhall, F. H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5717 · Cited by 288
Kawaguchi, T., Ando, M., Asami, K., Okano, Y., Fukuda, M., Nakagawa, H., Ibata, H., Kozuki, T., Endo, T., Tamura, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.4694 · Cited by 260
Docetaxel-related side effects and their management
Baker, J., Ajani, J., Scotté, F., Winther, D., Martin, M., Aapro, M. S., & von Minckwitz, G. (2009) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2008.10.003 · Cited by 261
Ahn, M.-J., Tanaka, K., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo, M., Pérol, M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01544 · Cited by 244
Di Maio, M., Chiodini, P., Georgoulias, V., Hatzidaki, D., Takeda, K., Wachters, F. M., Gebbia, V., Smit, E. F., Morabito, A., Gallo, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5844 · Cited by 181
Lee, D. H., Park, K., Kim, J. H., Lee, J.-S., Shin, S. W., Kang, J.-H., Ahn, M.-J., Ahn, J. S., Suh, C., & Kim, S.-W. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1903 · Cited by 179
Self-citationKarampeazis, A., Voutsina, A., Souglakos, J., Kentepozidis, N., Giassas, S., Christofillakis, C., Kotsakis, A., Papakotoulas, P., Rapti, A., Agelidou, M., et al. (2013) · Cancer · doi:10.1002/cncr.28132 · Cited by 113
Kubota, K., Kawahara, M., Ogawara, M., Nishiwaki, Y., Komuta, K., Minato, K., Fujita, Y., Teramukai, S., Fukushima, M., & Furuse, K. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70261-4 · Cited by 75
Immune checkpoint inhibitors in older adults
Elias, R., Morales, J., Rehman, Y., & Khurshid, H. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0534-9 · Cited by 59
Pallis, A. G., Agelaki, S., Agelidou, A., Varthalitis, I., Syrigos, K., Kentepozidis, N., Pavlakou, G., Kotsakis, A., Kontopodis, E., & Georgoulias, V. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-633 · Cited by 36
Kikuchi, R., Takoi, H., Tsuji, T., Nagatomo, Y., Tanaka, A., Kinoshita, H., Ono, M., Ishiwari, M., Toriyama, K., Kono, Y., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13792 · Cited by 15
Metadata
- Authors
- Fossella, F. V., DeVore, R., Kerr, R. N., Crawford, J., Natale, R. R., Dunphy, F., Kalman, L., Miller, V., Lee, J. S., Moore, M., Gandara, D., Karp, D., Vokes, E., Kris, M., Kim, Y., Gamza, F., Hammershaimb, L., & the TAX Non–Small-Cell Lung Cancer Study Group
- Venue
- Journal of Clinical Oncology
- Published
- 2000-06-12
- Volume
- 18
- Issue
- 12
- Pages
- 2354-2362
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1839238860
- Cited by
- 1,360
- References
- 9
- FWCI
- 58.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.